EY Chief Software Engineer Conducting a Quality Assessment Meeting

How health care executives feel about advances in AI

While legitimate concerns remain, EY survey respondents increasingly recognize the positive impact of the technology.

In brief
  • Nearly every respondent in the sector (94%) believes AI will enhance productivity and efficiency, better enabling them to focus on higher-value tasks.
  • Yet 83% also express concern about AI being used to personalize medical plans or help with diagnoses. Even more see the need for human supervision.

From the front lines of providers to the back offices of payers, generative AI (GenAI) is poised to be a transformative force across the health care and life sciences sectors — streamlining administrative tasks and redefining patient experiences, if handled thoughtfully and responsibly. In a heavily regulated industry like ours, introducing artificial intelligence (AI) into the workplace can create pathways to better care as well as tensions with employees and risks that must be managed.

Consolidating the views of employees across ranks and sectors, the pioneering EY AI Anxiety in Business Survey broadly reveals how people think about AI and its impact on their jobs — and considerations about how companies should communicate their AI intentions for greater success. A deeper look at the responses of 66 health care and life sciences executives at the VP level or above specifically reveals that 85% think AI adoption is not happening quick enough in the workplace. Further, 89% are anxious about falling behind and losing out on promotions without AI technology and more than half (53%) report having incorporated AI into their daily work.

Here are two trends worth highlighting as hospitals, insurers, pharma players and others plot their AI journeys.

1. AI garners widespread trust — but not enough for patient care currently

Nearly every health care executive surveyed (96%) say they trust AI, with 94% seeing it as a positive force in their workplace and 91% believing it has a positive effect on society as a whole. This is a promising foundation among executives near the highest ranks for building a more efficient future for the sector. 

Notably, 95% of the executives have advocated for the use of AI in their organizations, and around 72% of their organizations are using GenAI currently. Furthermore, 94% of the health care respondents believe that AI will enhance productivity and efficiency and allow them to focus on higher-value tasks.

The next step for executives is crafting the right value-added roadmap for moving forward amid such a high level of engagement. But the data reveals negative aspects as well, highlighting the importance of crafting a culture of awareness to understand how GenAI works, how it abides by regulation and how to scale responsibly while adding value.

A significant 85% of health care executives express worry about AI in the workplace in general, with this fear increasing for 62% of executives compared with the previous year. And 83% are concerned about AI being involved in personalizing medical plans or aiding in medical diagnoses. An overwhelming 91% believe AI needs human supervision, highlighting the importance of a human element in AI applications.

Additionally, 88% are comfortable with the use of AI in the hiring process, and over 50% prefer for the technology to be leveraged in tasks such as creating meeting notes, answering basic customer questions, analyzing data and forecasting trends, versus having humans perform those tasks on their own. While this suggests that the sector may be ready to embrace AI for administrative tasks (such as appointment scheduling, back-office functions and perhaps even patient education), barriers remain when considering the technology for helping with tasks directly tied to patient outcomes.

This aligns with a recent EY report on building the GenAI foundation in health care, showing how back-office use cases — such as billing, claims, waste reduction, scheduling and compliance — provide an entry point for getting comfortable with the technology and instituting proper data governance protocols. GenAI also shows promise in health care supply chains and drug discovery, while the next generation of patient care will likely rely on leveraging the technology with real-time, accurate biometric data through wearables. This evolution of patient monitoring can help prevent health conditions from escalating to crisis levels and move toward better quality of care.

How EY can help

  • smart-health

    Smart Health is about putting the patient at the heart of health services design, and reimagining models of care to realize personalized health at scale.

    Read more

2. Responsible AI, ethics and transparency should be core to the mission

 

But before we reach that point, health care organizations must establish frameworks for protecting stakeholders and mitigating risks. In the same sample of executives, 85% say they would have a more positive view of an organization that uses AI if it focused on ethics and responsibility and was transparent about use.

 

In the overall survey, employees across sectors and generations shared that they wanted to know more about leading AI practices through routine updates, given how quickly the technology is evolving. Employees also express trepidation about what constitutes responsible, legal and ethical use and what does not. Specifically, they want more training in the legal implications of AI, cybersecurity risks and AI ethics, the survey showed.

 

A comprehensive AI governance framework in health care requires embracing responsible AI principles like transparency, accuracy, fairness and human-centricity — in turn driving security, sustainability and explainability. Such a framework should be founded in a health care organization’s values and duty to comply with regulation, yet also be flexible enough to inspire further innovation and continue to evolve in a dynamic landscape.

 

This is no easy task, and often a trusted advisor can help develop this crucial roadmap. The EY principles on AI are publicly available and guide everything we do with the technology. As just one example of our work with clients, our professionals assisted a pharma giant with its AI risk management in its industry, providing confidence in its approach and highlighting opportunities for improvement (especially as the European Union was unveiling new AI regulations).

 

In another instance, our professionals helped an insurance provider use natural language processing to custom-train an algorithm to extract requirements that would then populate a central database, enabling the company’s analysts to rapidly search key words, phrases and characters by both state and business function. The new database significantly reduced the manual search time from about 250 hours to 15 minutes.

 

As the industry ventures forward, it is crucial to prioritize transparency, build trust with stakeholders and establish clear frameworks for AI governance. By addressing these concerns and fostering collaboration among health care professionals, technologists and ethicists, the industry can leverage GenAI to usher in a new era of efficient, effective and patient-centered care. The next steps involve not only developing the technology further but also creating clear guidelines and educational programs to ensure responsible and ethical implementation across the health care system.

Summary

Generative AI has the potential to enhance efficiency and patient care, but an EY survey reveals nuances in how executives are thinking about the technology. About 85% believe AI adoption is too slow, with many fearing they’ll fall behind without it. While 96% trust AI, 83% worry about its role in patient care decisions. Executives advocate for AI in administrative tasks but stress the need for human oversight. Ethical and transparent AI practices are crucial, with 85% favoring organizations prioritizing these values. The sector must navigate AI’s potential responsibly, balancing innovation with ethical considerations for the future of patient care.

Related articles

How a medical system builds a healthier cybersecurity program

EY and a large medical facility team up to reduce cyber risk and better protect patient data with EY cyber managed services. Learn more in this case study.

Abby Johnson + 1

How to build a foundation in AI to accelerate health transformation

Using AI to speed health care transformation and add value will require executives to strategize current work and architect for the future. Learn more.

Aloha McBride

How pharma can benefit from using GenAI in drug discovery

Using GenAI in drug discovery is a hot topic in the pharmaceutical industry, with speed and cost savings seen as potential benefits. Learn more.

Ranu Carroll + 1

    EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.